12,061 results match your criteria methotrexate mtx

Methotrexate versus expectant management in ectopic pregnancy: a meta-analysis.

Arch Gynecol Obstet 2021 Sep 15. Epub 2021 Sep 15.

Department of Nephrology, Dr. Ziauddin Hospital, Karachi, Pakistan.

Background: Ectopic pregnancy (EP) affects 1-2% of all pregnant females'(Barnhart et al., Expert Opin Pharmacother 2(3):409-417, 2001) that can require emergent surgical intervention. Noninvasive diagnostic tests like transvaginal ultrasound (TVUS), and serial β-hCG levels have enabled early diagnosis and allowed medical therapy to be tried. Read More

View Article and Full-Text PDF
September 2021

Genomic and transcriptomic analyses reveal a tandem amplification unit of 11 genes and mutations in mismatch repair genes in methotrexate-resistant HT-29 cells.

Exp Mol Med 2021 Sep 14. Epub 2021 Sep 14.

Asian Genome Institute, Seoul National University Bundang Hospital, Seongnamsi, 13605, Korea.

DHFR gene amplification is commonly present in methotrexate (MTX)-resistant colon cancer cells and acute lymphoblastic leukemia. In this study, we proposed an integrative framework to characterize the amplified region by using a combination of single-molecule real-time sequencing, next-generation optical mapping, and chromosome conformation capture (Hi-C). We identified an amplification unit spanning 11 genes, from the DHFR gene to the ATP6AP1L gene position, with high adjusted interaction frequencies on chromosome 5 (~2. Read More

View Article and Full-Text PDF
September 2021

The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success" in RA patients.

Arthritis Res Ther 2021 Sep 14;23(1):239. Epub 2021 Sep 14.

Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Charite Campus Mitte, Rheumatologisches Forschungslabor - AG Skriner, Chariteplatz 1 (intern Virchowweg 11, 5.OG, R011), 10117, Berlin, Germany.

Background: There is a need for biomarker to identify patients "at risk" for rheumatoid arthritis (risk-RA) and to better predict the therapeutic response and in this study we tested the hypothesis that novel native and citrullinated heterogeneous nuclear ribonucleoprotein (hnRNP)-DL autoantibodies could be possible biomarkers.

Methods: Using protein macroarray and ELISA, epitope recognition against hnRNP-DL was analysed in sera from different developed RA disease and diagnosed SLE patients. Toll-like receptor (TLR) 7/9 and myeloid differentiation primary response gene 88 (MyD88)-dependency were studied in sera from murine disease models. Read More

View Article and Full-Text PDF
September 2021

Genome-wide association study of liver enzyme elevation in rheumatoid arthritis patients starting methotrexate.

Pharmacogenomics 2021 Sep 15. Epub 2021 Sep 15.

Department of Medical Sciences, Clinical Pharmacogenomics & Science for Life Laboratory, Uppsala University, SE-751 85, Uppsala, Sweden.

To identify novel genetic variants predisposing to elevation of Alanine aminotransferase (ALT) in rheumatoid arthritis (RA) patients after initiation of methotrexate (MTX) treatment. We performed genome-wide association studies in 198 RA patients starting MTX. Outcomes were maximum level of ALT and ALT >1. Read More

View Article and Full-Text PDF
September 2021

Programmed cell death-ligand 1 (PD-L1) tumour cells and low-reacting programmed cell death 1 (PD1) tumour-infiltrating lymphocytes predict poor prognosis in Epstein-Barr virus diffuse large B-cell lymphoma.

Clin Exp Med 2021 Sep 13. Epub 2021 Sep 13.

Graduate School of Medical Sciences, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 8140180, Japan.

Epstein-Barr virus (EBV) diffuse large B-cell lymphoma (DLBCL) has specific tumour cell characteristics, and these patients have worse outcomes than EBV-negative DLBCL patients. We compared 38 EBV DLBCL patients with 43 methotrexate-associated EBV B-cell lymphoproliferative disorders (MTX/EBV BLPDs) and 30 non-germinal centre (GC) subtype DLBCL. Lymphoma cells of the EBV DLBCL group were positive for BCL2 in 17 patients (44. Read More

View Article and Full-Text PDF
September 2021

Development of Graves' disease during drug-free remission of juvenile dermatomyositis.

Mod Rheumatol Case Rep 2021 Sep 10. Epub 2021 Sep 10.

Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaidô, Japan.

We report a Japanese boy with Graves' disease (GD) which developed during drug-free remission of juvenile dermatomyositis (JDM). He had been diagnosed with JDM at the age of 6 years by typical skin rashes, muscle weakness, elevated serum transaminase levels, and typical findings of both magnetic resonance imaging and muscle biopsy. Although anti-melanoma differentiation antigen 5 autoantibody was positive, there was no complication of interstitial lung disease. Read More

View Article and Full-Text PDF
September 2021

Early intra-articular corticosteroid injection is predictors of remission of juvenile idiopathic arthritis.

Minerva Pediatr (Torino) 2021 Sep 13. Epub 2021 Sep 13.

Department of clinical and Experimental Medicine, University of Catania, Catania Italy.

Background: to assess predictors of remission in children with Juvenile Idiopathic Arthritis (JIA), treated with intraarticular corticosteroid injection (IACI) as monotherapy or in combination with Methotrexate (MTX).

Methods: a retrospective study of 43 patients diagnosed with different JIA subtypes and followed-up at a tertiary centre between 2000 and 2014. We included patients treated with IACI as monotherapy or in combination with MTX at onset or thereafter. Read More

View Article and Full-Text PDF
September 2021

Differentially expressed miRNAs in bone after methotrexate treatment.

J Cell Physiol 2021 Sep 12. Epub 2021 Sep 12.

Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.

Previous studies have shown that administration of antimetabolite methotrexate (MTX) caused a reduced trabecular bone volume and increased marrow adiposity (bone/fat switch), for which the underlying molecular mechanisms and recovery potential are unclear. Altered expression of microRNAs (miRNAs) has been shown to be associated with dysregulation of osteogenic and/or adipogenic differentiation by disrupting target gene expression. First, the current study confirmed the bone/fat switch following MTX treatment in precursor cell culture models in vitro. Read More

View Article and Full-Text PDF
September 2021

Novel Methotrexate-Ciprofloxacin Loaded Alginate-Clay Based Nanocomposite as Anticancer and Antibacterial Co-Drug Delivery System.

Adv Pharm Bull 2021 May 1;11(3):477-489. Epub 2020 Jul 1.

Drug Applied Research Center and Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

In last decades, by increasing multi-drug resistant microbial pathogens an urgent demand was felt in the development of novel antimicrobial agents. Promising nanocomposites composed of clay/alginate/imidazolium-based ionic liquid, have been developed via intercalation of calcium alginate and ionic liquid by ion exchange method. These tailored nanocomposites were used as nanocarriers to simultaneously deliver methotrexate (MTX), and ciprofloxacin (CIP), as anticancer and antibacterial agents, respectively to MCF-7 breast cancer cells. Read More

View Article and Full-Text PDF

Effect of Uterine Arterial Chemoembolization Combined with Ultrasound-Guided Uterine Curettage on Cervical Pregnancy and Influencing Factors.

Evid Based Complement Alternat Med 2021 1;2021:4609497. Epub 2021 Sep 1.

Department of Ultrasonography, Changxing County People's Hospital, Huzhou, Zhejiang Province 313100, China.

This is a retrospective study to analyze the efficacy of uterine artery chemoembolization (UACE) combined with ultrasound-guided curettage in the treatment of cervical pregnancy and the factors affecting the postoperative outcome. A total of 26 subjects were included in the study and were divided into a control group of 12 and an observer group of 14, all patients with cervical pregnancy diagnosed in our hospital from January 2016 to January 2020. Patients in the control group were treated with methotrexate injection (MTX) combined with ultrasound-guided curettage in our hospital, while the observer group was treated with UACE combined with ultrasound-guided curettage. Read More

View Article and Full-Text PDF
September 2021

Primary Versus Secondary NAFLD: Perspective on Advanced Fibrosis.

J Clin Exp Hepatol 2021 Sep-Oct;11(5):557-564. Epub 2020 Dec 31.

Department of Gastroenterology, Seth G.S. Medical College and KEM Hospital, Mumbai, India.

Background: The presence of macrovesicular steatosis on liver biopsy is the commonest histopathological finding. Nonalcoholic fatty liver disease (NAFLD) is the presence of ≥5% macrovesicular steatosis without significant alcohol use. It is subdivided into primary and secondary NAFLD; information on their differences is limited. Read More

View Article and Full-Text PDF
December 2020

Factors Associated with Pneumocystis jirovecii Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study.

Intern Med 2021 Sep 11. Epub 2021 Sep 11.

Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan.

Objective To investigate the risk factors for the development of Pneumocystis jirovecii pneumonia (PCP) in patients with rheumatoid arthritis (RA) undergoing methotrexate (MTX) therapy. Method This single-center retrospective cohort study included consecutive patients with RA who received MTX for at least one year. The study population was divided into PCP and non-PCP groups, depending on the development of PCP, and their characteristics were compared. Read More

View Article and Full-Text PDF
September 2021

The effectiveness of methotrexate and low-dose steroid therapy in the treatment of idiopathic granulomatous mastitis.

Adv Clin Exp Med 2021 Sep 9. Epub 2021 Sep 9.

Genesis Hospital, Department of General Surgery, Diyarbakır, Turkey.

Background: Idiopathic granulomatous mastitis (IGM) is a rare, chronic, benign, inflammatory breast disease of unknown cause. Patients usually present with a single breast mass, hyperemia, discharge, skin disorders, and fever. Radiological and clinical findings can mimic carcinoma and infection. Read More

View Article and Full-Text PDF
September 2021

Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.

Clin Rheumatol 2021 Sep 12. Epub 2021 Sep 12.

Pfizer Inc., Collegeville, PA, USA.

Objective: Analyze tofacitinib efficacy and safety by background methotrexate (MTX) dose in patients with psoriatic arthritis (PsA).

Methods: This post hoc analysis pooled data from two phase III, double-blind trials (OPAL Broaden, NCT01877668; OPAL Beyond, NCT01882439) including patients receiving tofacitinib 5 or 10 mg twice daily (BID), or placebo, with stable MTX. Efficacy outcomes at month 3 stratified by MTX dose (≤ 15 month 3 stratified by MTX dose vs > 15 mg/week) were American College of Rheumatology (ACR)20/50/70, Health Assessment Questionnaire-Disability Index (HAQ-DI); Psoriasis Area and Severity Index (PASI)50/75; change from baseline in HAQ-DI; physician's global assessment of PsA (PGA-PsA-visual analog scale [VAS]); patient's global joint and skin assessment (PGJS-VAS), Leeds Enthesitis Index (LEI); and Dactylitis Severity Score (DSS). Read More

View Article and Full-Text PDF
September 2021

Sarilumab monotherapy versus sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.

Rheumatology (Oxford) 2021 Sep 11. Epub 2021 Sep 11.

Department of Rheumatology, Leiden University, Leiden, the Netherlands.

Objective: Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs, such as methotrexate (MTX), has demonstrated improvement in clinical outcomes in patients with RA. The primary objective of this post hoc analysis was to compare the efficacy of sarilumab (200 mg every 2 weeks) monotherapy (MONARCH study) with that of sarilumab and MTX combination therapy (MOBILITY study) at week 24.

Methods: The endpoints assessed were mean change from baseline in the Clinical Disease Activity Index (CDAI), 28-joint Disease Activity using C-Reactive Protein (DAS28-CRP), CRP, haemoglobin (Hb), pain visual analogue scale (VAS) and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue. Read More

View Article and Full-Text PDF
September 2021

Human placental extract ameliorates methotrexate-induced hepatotoxicity in rats via regulating antioxidative and anti-inflammatory responses.

Cancer Chemother Pharmacol 2021 Sep 10. Epub 2021 Sep 10.

Department of Zoology, Faculty of Science, Damanhour University, Damanhour, Egypt.

Purpose: Methotrexate (MTX) induces hepatotoxicity, limiting its clinical efficacy as a widely known chemotherapy drug. In the current study, we examined the protective effect of human placenta extract (HPE) against MTX-induced liver damage in rats, as well as its ability to regulate antioxidative and anti-inflammatory liver responses.

Methods: Male rats were orally administered MTX at a daily dose of 5 mg/kg-body-weight in the presence or absence of HPE (10. Read More

View Article and Full-Text PDF
September 2021

Methotrexate Ameliorates Systemic Inflammation and Septic Associated-Lung Damage in a Cecal Ligation and Puncture Septic Rat Model.

Int J Mol Sci 2021 Sep 4;22(17). Epub 2021 Sep 4.

Institut d' Investigació i Innovació Parc Taulí (I3PT), 08201 Sabadell, Spain.

Background: Sepsis is a serious, heterogeneous clinical entity produced by a severe and systemic host inflammatory response to infection. Methotrexate (MTX) is a folate-antagonist that induces the generation of adenosine and also inhibits JAK/STAT pathway; MTX it is widely used as an anti-inflammatory drug to control the immune system.

Objective: The aim of this study was to assess the beneficial effects of a single and low dose of MTX in the systemic response and acute lung injury (ALI) induced by sepsis. Read More

View Article and Full-Text PDF
September 2021

Predictors of response to etanercept-methotrexate treatment: a post hoc logistic regression analysis of a randomized, open-label study in Latin American patients with rheumatoid arthritis.

Adv Rheumatol 2021 09 8;61(1):56. Epub 2021 Sep 8.

Pfizer, Collegeville, PA, USA.

Background: Determining potential predictors of clinical response would allow a more personalized rheumatoid arthritis (RA) treatment approach in heterogeneous populations such as Latin American (LA) patients.

Methods: Post hoc analysis to identify baseline characteristics predictive of clinical remission in response to treatment with etanercept (ETN) plus methotrexate (MTX) in LA patients with moderate to severe MTX-resistant RA. We report data from the group of patients who received ETN 50 mg/week plus MTX (ETN + MTX, n = 281) in a clinical trial consisting of an initial 24-week open-label phase, followed by a 104-week extension. Read More

View Article and Full-Text PDF
September 2021

Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available.

Front Pediatr 2021 19;9:635152. Epub 2021 Aug 19.

Pediatric Nephrology, Vall d'Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

High dose methotrexate (HDMTX) is used for the treatment of pediatric hemato-oncological diseases. HDMTX can induce acute kidney injury in cases of delayed elimination. The use of leucovorin remains the most effective rescue action. Read More

View Article and Full-Text PDF

Polymyalgia rheumatica: A case series from Colombia and analysis of Latin America.

J Transl Autoimmun 2021 21;4:100115. Epub 2021 Aug 21.

Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.

Objective: Polymyalgia rheumatica (PMR) is the most common inflammatory disease in patients over 50 years. Information about the disease in Latin America (LATAM) is scarce. We aimed to evaluate a group of Colombian patients with PMR and to conduct a systematic review of PMR in LATAM. Read More

View Article and Full-Text PDF

The modulatory impacts of extract against methotrexate-induced testicular dysfunction and oxidative stress.

Toxicol Res (Camb) 2021 Aug 7;10(4):677-686. Epub 2021 Jun 7.

Biochemistry Department, Faculty of Veterinary Medicine, Benha University, Benha 13736, Egypt.

root (licorice) is a widely used herb for its beneficial effects on health. This study explored the protective effects of licorice extract against oxidative stress and testicular dysfunction caused by methotrexate (MTX). Mice were allocated into (i) negative control group that received saline; (ii) licorice extract group, orally administered with 200 mg/kg body weight (bw) licorice extract for 12 days; (iii) positive MTX-intoxicated group, injected with a single intraperitoneal dose of MTX (20 mg/kg bw) on day 7; and (iv) a protective group that received licorice extract for 12 days and then MTX on day 7 as in groups 2 and 3. Read More

View Article and Full-Text PDF

Repurposing Methotrexate in Dampening SARS-CoV2-S1-Mediated IL6 Expression: Lessons Learnt from Lung Cancer.

Inflammation 2021 Sep 3. Epub 2021 Sep 3.

National Brain Research Centre, Manesar, Gurgaon, Haryana, 122 052, India.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) is associated with uncontrolled inflammatory responses. Loss of pulmonary angiotensin-converting enzyme 2 (ACE2) function has been associated with SARS-CoV-2 infection. The aberrant signalling and dysregulated inflammation characteristic of lung cancer have marked similarities with SARS-CoV-2 infection. Read More

View Article and Full-Text PDF
September 2021

Predictive factors of treatment success in two-dose methotrexate regimen in ectopic tubal pregnancy: A retrospective study.

Pak J Med Sci 2021 Sep-Oct;37(5):1309-1312

Dr. Keziban Dogan Department of Obstetrics and Gynecology, Health Sciences University, Bakirkoy, Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

Objectives: To investigate the predictive factors of success or failure in treating ectopic tubal pregnancies with two-dose methotrexate (MTX).

Methods: The records of patients treated for tubal EP with two-dose MTX were retrospectively reviewed. Patients were divided into two groups; the Group-I (failure) consisted of patients who did not respond to MTX therapy and the Group-II (success) included patients who were successfully treated with MTX. Read More

View Article and Full-Text PDF
February 2021

The first case of methotrexate-associated lymphoproliferative disorder presenting as follicular T-cell lymphoma.

Pathol Int 2021 Sep 2. Epub 2021 Sep 2.

Department of Pathology, National Hospital Organization, Kumamoto Medical Center, Kumamoto, Japan.

This is the first case of follicular T-cell lymphoma (FTCL) presenting as methotrexate-associated lymphoproliferative disorders (MTX-LPDs). A 69-year-old man treated rheumatoid arthritis with methotrexate presented with cervical swelling, hoarseness and fever. Imaging studies revealed multiple lymphadenopathy and lymphoma was suspected. Read More

View Article and Full-Text PDF
September 2021

Complete ablation of tumors using synchronous chemoradiation with bimetallic theranostic nanoparticles.

Bioact Mater 2022 Jan 12;7:74-84. Epub 2021 Jun 12.

Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.

Synchronous chemotherapy and radiotherapy, termed chemoradiation therapy, is now an important standard regime for synergistic cancer treatment. For such treatment, nanoparticles can serve as improved carriers of chemotherapeutics into tumors and as better radiosensitizers for localized radiotherapy. Herein, we designed a Schottky-type theranostic heterostructure, BiS-Au, with deep level defects (DLDs) in BiS as a nano-radiosensitizer and CT imaging contrast agent which can generate reactive free radicals to initiate DNA damage within tumor cells under X-ray irradiation. Read More

View Article and Full-Text PDF
January 2022

Use of Intravitreal Methotrexate Infusion in Complicated Retinal Detachment for Prevention of Proliferative Vitreoretinopathy in a Pilot Study.

Cureus 2021 Aug 25;13(8):e17439. Epub 2021 Aug 25.

Surgery, Ophthalmology, The Aga Khan University Hospital, Karachi, PAK.

Objective The objective of this pilot study was to evaluate the efficacy and safety of per-operative intravitreal methotrexate (MTX) infusion during vitrectomy in patients of retinal detachment (RD) with advanced grade proliferative vitreoretinopathy (PVR). Methods In this prospective interventional case series, we included patients with Grade C PVR, recurrent RD, and open globe trauma. All patients underwent standard single surgeon operated 23-gauge pars plana vitrectomy (PPV) with 80mg of MTX in 1000mL of irrigation fluid. Read More

View Article and Full-Text PDF

Single-dose methotrexate-based protocol for the treatment of caesarean scar pregnancy and successive pregnancy outcomes.

Hum Fertil (Camb) 2021 Aug 29:1-7. Epub 2021 Aug 29.

Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, Tel-Aviv, and the Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

The incidence of caesarean scar pregnancy (CSP) increases in recent years. Yet, the best mode of treatment and its effects on successive pregnancies is not well established. The aim of this study was to investigate the success rate of single-dose methotrexate (MTX) in the management of CSP, and the outcomes of subsequent pregnancies in a retrospective cohort study. Read More

View Article and Full-Text PDF

Molecular toxicity of methotrexate in rheumatoid arthritis treatment: A novel perspective and therapeutic implications.

Toxicology 2021 Aug 25;461:152909. Epub 2021 Aug 25.

Department of Biomedical Sciences, School of Biosciences and Technology, VIT, Vellore, Tamil Nadu, India. Electronic address:

Rheumatoid arthritis (RA) is an autoimmune inflammatory systematic complication which is a chronic disorder that severely affects bones and joints and results in the quality of life impairment. Methotrexate (MTX), an FDA-approved drug has maintained the standard of care for treating patients affected with RA. The mechanism of MTX includes the inhibition of purine and pyrimidine synthesis, suppression of polyamine accumulation, promotion of adenosine release, adhesion of the inflammatory molecules, and controlling of cytokine cascade in RA. Read More

View Article and Full-Text PDF

Pharmacokinetics and Toxicity Evaluation of a PLGA and Chitosan-Based Micro-Implant for Sustained Release of Methotrexate in Rabbit Vitreous.

Pharmaceutics 2021 Aug 9;13(8). Epub 2021 Aug 9.

Department of Mechanical and Materials Engineering, University of Cincinnati, Cincinnati, OH 45221, USA.

The present research investigates the pharmacokinetics and toxicity of a chitosan (CS) and poly(lactic-co-glycolic) acid (PLGA)-based methotrexate (MTX) intravitreal micro-implant in normal rabbit eyes. PLGA and CS-based micro-implants containing 400 µg of MTX were surgically inserted in the vitreous of twenty-four New Zealand rabbits using minimally invasive procedures. The PLGA-coated CS-MTX micro-implant and the placebo micro-implant were inserted in the right eye and in the left eye, respectively, of each rabbit. Read More

View Article and Full-Text PDF

Regulation of Keap-1/Nrf2/AKT and iNOS/NF-κB/TLR4 signals by apocynin abrogated methotrexate-induced testicular toxicity: Mechanistic insights and computational pharmacological analysis.

Life Sci 2021 Aug 25;284:119911. Epub 2021 Aug 25.

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt.

Aim: Male reproductive toxicity is becoming of growing significance due to clinical chemotherapy usage. Methotrexate (MTX) is an anti-folate used on a large scale for different tumors and autoimmune conditions. Despite its wide clinical use, MTX is associated with severe testicular intoxication. Read More

View Article and Full-Text PDF